The global choroidal neovascularization market size reached US$ 6.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.0% during 2022-2028. Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE). Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision. At present, a combination of procedures, such as fluorescein angiography (FA), indocyanine green (ICG) angiography and optical coherence tomography (OCT) scanning, are utilized for diagnosing CNV. As per the results, doctors then prescribe anti-vascular endothelial growth factor (VEGF) drugs, thermal laser treatment and photodynamic therapy (PDT), to prevent the growth of the blood vessels. The market is experiencing growth on account of the rising prevalence of age-related macular degeneration (ARMD), ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears and inflammatory diseases of the choroid and retina. Moreover, the increasing geriatric population, which is more vulnerable to serious health conditions, is acting as another key factor bolstering the market growth. Furthermore, the growing adoption of combination drugs, along with the introduction of long-lasting anti-VEGF drugs, is propelling the demand for CNV treatments worldwide. Other factors, such as improving healthcare infrastructure and the increasing investments in research and development (R&D) activities, are also contributing to the growth of the market. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global choroidal neovascularization market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, type of diagnosis, treatment type and application. Breakup by Product Type: Intravenous Intravitreal Breakup by Type of Diagnosis: Fluorescein Angiography (FA) Indocyanine Green (ICG) Angiography Spectral Domain Optical Coherence Tomography (OCT) Others Breakup by Treatment Type: Angiogenesis Inhibitors Injection Photodynamic Therapy Laser photocoagulation Low-dose Radiation Therapy Surgery Breakup by Application: Extreme Myopia Malignant Myopic Degeneration Age-Related Developments Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., F. Hoffmann-La Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Regeneron Pharmaceuticals Inc. and Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.). Key Questions Answered in This Report: How has the global choroidal neovascularization market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global choroidal neovascularization market? What are the key regional markets? What is the breakup of the market based on the product type? What is the breakup of the market based on the type of diagnosis? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the application? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global choroidal neovascularization market and who are the key players? What is the degree of competition in the industry?

1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Choroidal Neovascularization Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product Type 6.1 Intravenous 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Intravitreal 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Type of Diagnosis 7.1 Fluorescein Angiography (FA) 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Indocyanine Green (ICG) Angiography 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Spectral Domain Optical Coherence Tomography (OCT) 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Treatment Type 8.1 Angiogenesis Inhibitors Injection 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Photodynamic Therapy 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Laser Photocoagulation 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Low-dose Radiation Therapy 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Surgery 8.5.1 Market Trends 8.5.2 Market Forecast 9 Market Breakup by Application 9.1 Extreme Myopia 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Malignant Myopic Degeneration 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Age-Related Developments 9.3.1 Market Trends 9.3.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast 11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Value Chain Analysis 13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Bausch Health Companies Inc 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 Bayer AG 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 Gilead Sciences, Inc 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 F. Hoffmann-La Roche AG 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 SWOT Analysis 15.3.5 MaaT Pharma 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.6 Novartis AG 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 Pfizer Inc 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 Quark Pharmaceuticals Inc. (SBI ALApharma Co., Limited) 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.9 Regeneron Pharmaceuticals Inc 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Sanwa Kagaku Kenkyusho Co. Ltd. (SUZUKEN CO., LTD.) 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio